US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

MapLight Therapeutics / Equity Capital Markets

<ul>
<li>MapLight Therapeutics Inc. (MPLT) priced 14.75 million shares at $17.00 and opened at $19.00, marking an initial gain of 11.7% on first trade.</li>
<li>The offering included a $40 million anchor order from T. Rowe Price and a $8.1 million concurrent private placement led by Goldman Sachs.</li>
<li>Channel checks indicate the deal was multiple times oversubscribed, with strong participation from long-only mutual funds and high-quality healthcare specialists.</li>
</ul>


MapLight Therapeutics Inc. (MPLT) priced 14.75 million shares at $17.00 and opened at $19.00, marking an initial gain of 11.7% on first trade.
The offering included a $40 million anchor order from T. Rowe Price and a $8.1 million concurrent private placement led by Goldman Sachs.
Channel checks indicate the deal was multiple times oversubscribed, with strong participation from long-only mutual funds and high-quality healthcare specialists.


MapLight Therapeutics Inc. (MPLT): Oversubscribed Neuroscience IPO Launches with a Bright Start

<ul>
<li>Its prospectus reveals a $40 million anchor order from T. Rowe Price and an additional $8.1 million concurrent private placement through Goldman Sachs.</li>
<li>Additionally, according to guidance, the deal is already being classified by our sources as well-oversubscribed on new and existing orders.</li>
<li>Given the company’s scientific credibility and strategic investor base, MapLight Therapeutics appears well-positioned to navigate the current market.</li>
</ul>


Its prospectus reveals a $40 million anchor order from T. Rowe Price and an additional $8.1 million concurrent private placement through Goldman Sachs.
Additionally, according to guidance, the deal is already being classified by our sources as well-oversubscribed on new and existing orders.
Given the company’s scientific credibility and strategic investor base, MapLight Therapeutics appears well-positioned to navigate the current market.


Maplight Therapeutics (MPLT): Clubby Biotech Deal Anticipated as IPO Market Pushes Ahead

<ul>
<li>Maplight Therapeutics set terms for its IPO and can debut on the Nasdaq as early as October 27th. </li>
<li>Maplight is offering 17.25 million shares at $17.00 with the lead underwriters on the transaction being Morgan Stanley, Jefferies, Leerink and Stifel. </li>
<li>The company’s decision to wait through the 20-day effectiveness period amid the government shutdown underscores both patience and confidence in its investor base.</li>
</ul>


Maplight Therapeutics set terms for its IPO and can debut on the Nasdaq as early as October 27th. 
Maplight is offering 17.25 million shares at $17.00 with the lead underwriters on the transaction being Morgan Stanley, Jefferies, Leerink and Stifel. 
The company’s decision to wait through the 20-day effectiveness period amid the government shutdown underscores both patience and confidence in its investor base.


Maplight Therapeutics (MPLT): Schizophrenia and Alzheimer’s Disease Biotech Sets Terms for IPO

<ul>
<li>The company that describes itself as a biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system.</li>
<li>Morgan Stanley, Jefferies, Leerink Partners, Stifel are the bookrunners on this IPO.</li>
<li>Their lead product candidate, ML-007C-MA, is currently in a Phase II trial.</li>
</ul>


The company that describes itself as a biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system.
Morgan Stanley, Jefferies, Leerink Partners, Stifel are the bookrunners on this IPO.
Their lead product candidate, ML-007C-MA, is currently in a Phase II trial.


Maplight Therapeutics (MPLT): Peeking at the IPO Prospectus of Biotech Treating CNS Diseases

<ul>
<li>Lead asset EVO756 shows promising Phase 2 data in symptomatic dermographism, validating its MRGPRX2-targeting mechanism and supporting further expansion into atopic dermatitis.</li>
<li>A $115M Series C co-led by RA Capital and Sectoral Asset Management strengthens credibility and provides funding for multiple Phase 2 clinical programs.</li>
<li>Evommune’s IPO is multiple-times oversubscribed, driven by significant demand from healthcare-dedicated investors and mutual funds, signaling robust institutional interest.</li>
</ul>


Lead asset EVO756 shows promising Phase 2 data in symptomatic dermographism, validating its MRGPRX2-targeting mechanism and supporting further expansion into atopic dermatitis.
A $115M Series C co-led by RA Capital and Sectoral Asset Management strengthens credibility and provides funding for multiple Phase 2 clinical programs.
Evommune’s IPO is multiple-times oversubscribed, driven by significant demand from healthcare-dedicated investors and mutual funds, signaling robust institutional interest.


Evommune Inc. (EVMN): RA Capital Backed Biotech Tests the IPO Market

United States

MapLight Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on improving the lives of patients suffering from debilitating central nervous system disorders. MapLight Therapeutics operates in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

MapLight Therapeutics (MPLT US)

MapLight Therapeutics Inc. (MPLT): Oversubscribed Neuroscience IPO Launches with a Bright Start

MapLight Therapeutics Inc. (MPLT) sees strong investor demand, pricing IPO above range and opening with 11.7% gain on first trade.

IPO Boutique

Maplight Therapeutics (MPLT): Clubby Biotech Deal Anticipated as IPO Market Pushes Ahead

MapLight Therapeutics secures significant anchor order and private placement, poised for success with strong investor support and scientific...

IPO Boutique

Maplight Therapeutics (MPLT): Schizophrenia and Alzheimer’s Disease Biotech Sets Terms for IPO

Maplight Therapeutics sets IPO terms, offering 17.25 million shares at $17.00 with debut on Nasdaq possible by October 27th, showing patience and...

IPO Boutique

Maplight Therapeutics (MPLT): Peeking at the IPO Prospectus of Biotech Treating CNS Diseases

Biopharmaceutical company focused on CNS disorders set to go public with lead product in Phase II trial, backed by top bookrunners.

IPO Boutique

Evommune Inc. (EVMN): RA Capital Backed Biotech Tests the IPO Market

Phase 2 data for EVO756 in dermographism leads to successful $115M Series C funding and oversubscribed IPO for Evommune, signaling strong...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

MapLight Therapeutics Inc. (MPLT): Oversubscribed Neuroscience IPO Launches with a Bright Start

​MapLight Therapeutics Inc. (MPLT) sees strong investor demand, pricing IPO above range and opening with 11.7% gain on first trade.

IPO Boutique

Maplight Therapeutics (MPLT): Clubby Biotech Deal Anticipated as IPO Market Pushes Ahead

​MapLight Therapeutics secures significant anchor order and private placement, poised for success with strong investor support and scientific...

IPO Boutique

Maplight Therapeutics (MPLT): Schizophrenia and Alzheimer’s Disease Biotech Sets Terms for IPO

​Maplight Therapeutics sets IPO terms, offering 17.25 million shares at $17.00 with debut on Nasdaq possible by October 27th, showing patience and...

IPO Boutique

Maplight Therapeutics (MPLT): Peeking at the IPO Prospectus of Biotech Treating CNS Diseases

​Biopharmaceutical company focused on CNS disorders set to go public with lead product in Phase II trial, backed by top bookrunners.

IPO Boutique

Evommune Inc. (EVMN): RA Capital Backed Biotech Tests the IPO Market

Phase 2 data for EVO756 in dermographism leads to successful $115M Series C funding and oversubscribed IPO for Evommune, signaling strong...

IPO Boutique

MapLight Therapeutics Inc. (MPLT) sees strong investor demand, pricing IPO above range and opening with 11.7% gain on first trade.

MapLight Therapeutics secures significant anchor order and private placement, poised for success with strong investor support and scientific...

Maplight Therapeutics sets IPO terms, offering 17.25 million shares at $17.00 with debut on Nasdaq possible by October 27th, showing patience and...

Biopharmaceutical company focused on CNS disorders set to go public with lead product in Phase II trial, backed by top bookrunners.